drugset / Trial / NCT05671835
Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of oral daily administration of TTI-101 over a 12-week treatment duration in participants with idiopathic pulmonary fibrosis (IPF).
Timeline
- Start
- 2023-05-15
- Primary completion
- 2025-08-14
- Completion
- 2025-08-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | C-188-9 | Small molecule | 400 mg | Oral |
| Subject | C-188-9 | Small molecule | 800 mg | Oral |